David Alan Campbell Sells 8,072 Shares of Janux Therapeutics (NASDAQ:JANX) Stock

Janux Therapeutics, Inc. (NASDAQ:JANX) CEO David Alan Campbell sold 8,072 shares of Janux Therapeutics stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $13.73, for a total transaction of $110,828.56. Following the transaction, the chief executive officer directly owned 284,982 shares in the company, valued at approximately $3,912,802.86. This represents a 2.75% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Janux Therapeutics Price Performance

Shares of NASDAQ JANX traded down $0.15 during midday trading on Friday, reaching $13.65. The company’s stock had a trading volume of 1,533,974 shares, compared to its average volume of 2,182,684. The stock has a market capitalization of $821.05 million, a P/E ratio of -8.13 and a beta of 2.88. The firm has a 50 day moving average price of $22.51 and a 200-day moving average price of $23.74. Janux Therapeutics, Inc. has a 12-month low of $13.52 and a 12-month high of $61.59.

Janux Therapeutics (NASDAQ:JANX) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.39) EPS for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.21. The business had revenue of $10.00 million for the quarter, compared to the consensus estimate of $3.07 million. On average, equities analysts predict that Janux Therapeutics, Inc. will post -1.38 EPS for the current year.

Institutional Investors Weigh In On Janux Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of JANX. Walleye Capital LLC bought a new position in shares of Janux Therapeutics in the first quarter worth $307,000. MetLife Investment Management LLC lifted its holdings in Janux Therapeutics by 7.9% during the 1st quarter. MetLife Investment Management LLC now owns 18,663 shares of the company’s stock worth $504,000 after purchasing an additional 1,365 shares in the last quarter. Corebridge Financial Inc. boosted its stake in Janux Therapeutics by 11.2% in the 1st quarter. Corebridge Financial Inc. now owns 15,495 shares of the company’s stock worth $418,000 after purchasing an additional 1,555 shares during the period. Cubist Systematic Strategies LLC boosted its stake in Janux Therapeutics by 88.0% in the 1st quarter. Cubist Systematic Strategies LLC now owns 75,860 shares of the company’s stock worth $2,048,000 after purchasing an additional 35,511 shares during the period. Finally, Alyeska Investment Group L.P. grew its holdings in Janux Therapeutics by 18.5% during the 1st quarter. Alyeska Investment Group L.P. now owns 408,678 shares of the company’s stock valued at $11,034,000 after buying an additional 63,762 shares in the last quarter. Institutional investors own 75.39% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. Cantor Fitzgerald reduced their price target on shares of Janux Therapeutics from $200.00 to $150.00 and set an “overweight” rating for the company in a research report on Tuesday, December 2nd. HC Wainwright reduced their target price on shares of Janux Therapeutics from $70.00 to $45.00 and set a “buy” rating for the company in a research report on Tuesday, December 2nd. Barclays decreased their price target on shares of Janux Therapeutics from $48.00 to $29.00 and set an “overweight” rating for the company in a research note on Wednesday, December 17th. Truist Financial assumed coverage on Janux Therapeutics in a report on Wednesday, September 10th. They set a “buy” rating and a $100.00 price objective for the company. Finally, Stifel Nicolaus decreased their target price on Janux Therapeutics from $46.00 to $38.00 and set a “buy” rating for the company in a research report on Tuesday, December 2nd. Twelve research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $61.08.

Janux Therapeutics Company Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.